TB Online is no longer maintained. This is an archive of the site. For news on TB please go to: https://globaltbcab.org/

Items tagged with Treatment

Long-term Sirturo therapy safe, effective against MDR-TB (post)

Data presented at ECCMID 2016 showed that a 24-week or longer regimen of Sirturo was well-tolerated and effective against multidrug-resistant tuberculosis.

Children with tuberculosis in India suffer on lack of proper fixed-dose combinations (post)

Since 2010, evidence is emerging that doses to treat TB earlier thought to be optimal are less than what a child’s body needs, doctors say

India: WHO's shorter treatment for multidrug-resistant TB, city may not gain (post)

Mumbai, 13 May 2016: On Thursday , the World Health Organisation (WHO) gave its nod for an affordable drug combination that cuts down time needed to treat multi-drug resistant tuberculosis from 24 months to around nine months.

Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary TB (post)

A research team from Spain has prepared a Cochrane systematic review that explores the efficacy, safety, and adherence to fixed-dose combinations (FDCs) of drugs versus single-drug formulations to treat people who are newly diagnosed with tuberculosis (TB).

India: TB patients protest outside health ministry, promised proper drug regimes from July (post)

May 20, 2016 - A group of tuberculosis patients, protesting outside the Union health ministry in Delhi's searing mid-May heat, brought attention to the problem of India's outdated tuberculosis treatment, and forced the ministry officials to give assurance to provide patients with the fixed-dose combination (FDCs) medicines they urgently need.

Mumbai: Hope for multidrug-resistant TB patients (post)

Such patients will be getting treated with bedaquiline drug and their samples have been sent for testing to ensure that they are physically fit to be administered with the drug.

Page 20 of 108 · Total posts: 0

←First 19 20 21 Last→

The original material on this site is licensed under a Creative Commons Attribution 3.0 Unported License. Articles and images provided by 3rd-parties are subject to their licenses, though we strive to use free and open source materials wherever possible.
Creative Commons Licence badge